‘Hostile, but hooked’: What’s behind the US-China trade truce extension?

The US and China extended their trade truce for two months, preserving a pause in tariff escalation and delaying further Chinese rare-earth export restrictions, but analysts see little prospect of a durable agreement. Existing tariffs remain steep at 36.5% on Chinese goods entering the US and 31% on US goods entering China, leaving material risks to US consumer prices, corporate margins and Chinese export demand. China’s control of 60% of known rare-earth deposits and 90% of processing capacity remains a major leverage point, while technology controls, sanctions related to Russian oil, Taiwan and the AI rivalry could quickly unravel the truce.

Analysis

The market should treat the extension as a reduction in near-term headline risk, not a reopening of the China-exposed earnings trade. A short expiry preserves optionality for either side while preventing corporates from committing to multi-year sourcing, capex, or inventory plans; this sustains duplicative supply chains and working-capital intensity. The most durable beneficiaries are non-China critical-mineral and magnet supply-chain assets, while import-heavy consumer electronics, industrial automation, and EV assemblers retain a higher tariff-risk discount despite any immediate relief rally.

The key asymmetry is rare-earth licensing: a disruption would transmit first through defense, EV traction motors, wind turbines, and high-performance industrial equipment rather than broad semiconductor wafer supply. MP and Lynas (LYC.AX/LYSDY) have strategic scarcity value, but their equity upside depends on verified separation and magnet-output ramp rates, not simply another policy headline. RTX, LMT, NOC and GD face a less appreciated risk of delayed deliveries, higher procurement costs, and potentially fixed-price program margin pressure if magnet availability tightens; government cost recovery is slow and uneven.

Over the next days, the likely effect is lower trade-volatility and a tactical bid for China-sensitive cyclicals. Over the following 1-3 months, any failure to convert the pause into predictable licensing, tariff schedules, and enforcement mechanisms should revive inventory stockpiling and widen dispersion between domestically supplied strategic materials and China-dependent manufacturers. The contrarian view is that markets may overprice a broad inflation shock: firms have already diversified portions of final assembly, and a partial disruption would initially be absorbed through inventories; the larger risk is multiple compression from policy uncertainty, not an immediate CPI impulse. Falsify the defensive supply-chain thesis if licensing is extended with published volumes/durations and tariff reductions are locked in for at least 6-12 months.

Key Decisions for Investors

• Establish a 3-6 month tactical long in MP, sized modestly due to execution risk; use a 12-15% stop or reduce if the company misses separation/magnet-ramp milestones. Upside is a rerating on any credible non-China licensing disruption, but the thesis requires operational delivery rather than geopolitical rhetoric.
• Pair long MP (or LYC.AX for broader non-China exposure) versus short a basket of China-dependent industrial/consumer import exposure such as AAPL and TSLA only after a relief rally; target a 2-3 month horizon into the next truce deadline. Exit the pair if a durable tariff-and-licensing framework is published, as supplier diversification would erode the scarcity premium.
• Buy 3-6 month downside protection on XLI or a basket of RTX/LMT/NOC through puts rather than outright shorts. The exposure is to procurement delays and fixed-price defense margin risk if critical-material restrictions return; risk is limited to premium, and the hedge should be closed if verified rare-earth export approvals normalize.
• Maintain an alert around the January licensing deadline and any Taiwan-, sanctions-, or technology-control escalation. Do not add broad long China/US cyclicals without data on tariff coverage, exemption rates, and actual shipment volumes; those details determine whether earnings revisions, rather than sentiment, are justified.